Somatostatin vs Ziconotide
Head-to-head comparison of Somatostatin (Somatostatin-14) and Ziconotide (ω-Conotoxin MVIIA (ziconotide)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Somatostatin | Ziconotide |
|---|---|---|
| Category | Pain Management | Pain Management |
| Full Name | Somatostatin-14 | ω-Conotoxin MVIIA (ziconotide) |
| Molecular Weight | 1637.85 | 2639.1 Da |
| Half-Life | 1-3 min | approximately 4.5 hours |
| Amino Acids | 14 | 25 |
| Typical Dose | N/A|N/A | 0.5-19.2 mcg/day |
| Route | IV/SC | Intrathecal |
| Purity | ≥98% | ≥98% |
| Studies Count | 84 | 500 |
| Research Status | Approved | Approved |
Somatostatin Benefits
- ✓nociceptive inhibition
- ✓anti-inflammatory signaling
- ✓visceral pain modulation
Ziconotide Benefits
- ✓strong non-opioid analgesia
- ✓effective for refractory neuropathic pain
- ✓opioid-sparing option
- ✓intrathecal delivery allows targeted action
Somatostatin Dosing
N/A|N/A
Ziconotide Dosing
start 0.5 mcg/day intrathecal|titrate by 0.5 mcg/day no more than 2 times weekly|max 19.2 mcg/day in labeling
Somatostatin Side Effects
- ⚠hyperglycemia
- ⚠bradycardia
- ⚠GI upset
Ziconotide Side Effects
- ⚠dizziness
- ⚠confusion
- ⚠ataxia
Research Overview
Somatostatin
Somatostatin reduces release of multiple excitatory mediators and can suppress pain signaling in preclinical and limited translational work. Its analgesic use is not standard, but the peptide is real and mechanistically relevant to pain control.
Ziconotide
Clinical studies and post-marketing data support ziconotide as an analgesic for severe chronic pain that does not respond to conventional therapy. Research focuses on balancing analgesic efficacy with neuropsychiatric tolerability and careful dose titration.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.